Background: Epilepsy is a chronic disorder affecting all ages but with a peak in the elderly. The association of epilepsy with age can be explained by the predominance of brain diseases with epileptogenic potential (mostly stroke and dementia) and by the effects of the aging process through a number of molecular mechanisms involving networks of neurons with focal or diffuse distribution. Summary: The prevalence of active epilepsy is 6.4 per 1,000 and the lifetime prevalence is 7.6 per 1,000. The prevalence tends to increase with age, with peaks in the oldest age groups and in socially deprived individuals. The incidence of epilepsy is 61.4 per 100,000 person-years. Epilepsy has a bimodal distribution according to age with peaks in the youngest individuals and in the elderly. The increased incidence of seizures and epilepsy in the elderly can be attributed to the increase of age-related and aging-related epileptogenic conditions. Key Messages: As the world population is steadily growing with parallel increase in the number of aged subjects, in the future, epilepsy will represent a huge burden for the society. Measures must thus be taken to prevent seizures and epilepsy through the reduction of preventable epileptogenic factors.

1.
Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S: ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55: 475–482.
2.
Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993; 34: 592–596.
3.
Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA: Recommendation for a definition of acute symptomatic seizure. Epilepsia 2010; 51: 671–675.
4.
Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia 1995; 36: 327–333.
5.
Hauser WA, Hesdorffer DC: Genetics; in Hauser WA, Hesdorffer DC (eds): Epilepsy: Frequency, Causes and Consequences. New York, Demos Publications, 1990, pp 93–118.
6.
Hauser WA, Annegers JF, Kurland LT: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 1993; 34: 453–468.
7.
de Lores Arnaiz GR, Ordieres MG: Brain Na(+), K(+)-ATPase activity in aging and disease. Int J Biomed Sci 2014; 10: 85–102.
8.
Aguiar CC, Almeida AB, Araújo PV, de Abreu RN, Chaves EM, do Vale OC, Macêdo DS, Woods DJ, Fonteles MM, Vasconcelos SM: Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012; 2012: 795259.
9.
Costello DJ, Delanty N: Oxidative injury in epilepsy: potential for antioxidant therapy? Expert Rev Neurother 2004; 4: 541–553.
10.
Yang JL, Sykora P, Wilson DM 3rd, Mattson MP, Bohr VA: The excitatory neurotransmitter glutamate stimulates DNA repair to increase neuronal resiliency. Mech Ageing Dev 2011; 132: 405–411.
11.
Mattson MP: Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 2003; 3: 65–94.
12.
Waldbaum S, Patel M: Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res 2010; 88: 23–45.
13.
Hermann BP, Sager MA, Koscik RL, Young K, Nakamura K: Vascular, inflammatory, and metabolic factors associated with cognition in aging persons with -chronic epilepsy. Epilepsia 2017; 58:e152–e156.
14.
Bell GS, Neligan A, Sander JW: An unknown quantity – the worldwide prevalence of epilepsy. Epilepsia 2014; 55: 958–962.
15.
Thurman DJ, Beghi E, Begley CE, Berg AT, Buchhalter JR, Ding D, Hesdorffer DC, Hauser WA, Kazis L, Kobau R, Kroner B, Labiner D, Liow K, Logroscino G, Medina MT, Newton CR, Parko K, Paschal A, Preux PM, Sander JW, Selassie A, Theodore W, Tomson T, Wiebe S; ILAE Commission on Epidemiology: Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011; 52(suppl 7): 2–26.
16.
Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon CS, Dykeman J, Pringsheim T, Lorenzetti DL, Jetté N: Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology 2017; 88: 296–303.
17.
de la Court A, Breteler MM, Meinardi H, Hauser WA, Hofman A: Prevalence of epilepsy in the elderly: the Rotterdam Study. Epilepsia 1996; 37: 141–147.
18.
Parko K, Thurman DJ: Prevalence of epilepsy and seizures in the Navajo Nation 1998–2002. Epilepsia 2009; 50: 2180–2185.
19.
Schachter SC, Cramer GW, Thompson GD, Chaponis RJ, Mendelson MA, Lawhorne L: An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998; 46: 1137–1141.
20.
Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA: Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43: 1402–1409.
21.
Chin RF, Neville BG, Scott RC: A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004; 11: 800–810.
22.
Hauser WA, Annegers JF, Rocca WA: Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71: 576–586.
23.
Thurman DJ, Logroscino G, Beghi E, Hauser WA, Hesdorffer DC, Newton CR, Scorza FA, Sander JW, Tomson T; Epidemiology Commission of the International League Against Epilepsy: The burden of premature mortality of epilepsy in high-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017; 58: 17–26.
24.
Levira F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H, Odermatt P, Logroscino G, Newton CR; Epidemiology Commission of the International League Against Epilepsy: Premature mortality of epilepsy in low- and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017; 58: 6–16.
25.
Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA: Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001; 42: 1031–1035.
26.
Sillanpää M, Lastunen S, Helenius H, Schmidt D: Regional differences and secular trends in the incidence of epilepsy in Finland: a nationwide 23-year registry study. Epilepsia 2011; 52: 1857–1867.
27.
Cockerell OC, Eckle I, Goodridge DM, Sander JW, Shorvon SD: Epilepsy in a population of 6000 re-examined: secular trends in first attendance rates, prevalence, and prognosis. J Neurol Neurosurg Psychiatry 1995; 58: 570–576.
28.
GBD 2015 Neurological Disorders Collaborator Group: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 16: 877–897.
29.
Keezer MR, Sisodiya SM, Sander JW: Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol 2016; 15: 106–115.
30.
Friedman D, Honig LS, Scarmeas N: Seizures and epilepsy in Alzheimer’s disease. CNS Neurosci Ther 2012; 18: 285–294.
31.
Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y: Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 2006; 47: 867–872.
32.
Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L: Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol 2013; 70: 1158–1166.
33.
Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA: Dementia and adult-onset unprovoked seizures. Neurology 1996; 46: 727–730.
34.
Gaitatzis A, Sisodiya SM, Sander JW: The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012; 53: 1282–1293.
35.
Horváth A, Szűcs A, Barcs G, Noebels JL, Kamondi A: Epileptic seizures in Alzheimer disease: a review. Alzheimer Dis Assoc Disord 2016; 30: 186–192.
36.
Vossel KA, Tartaglia MC, Nygaard HB, -Zeman AZ, Miller BL: Epileptic activity in Alzheimer’s disease: causes and clinical relevance. Lancet Neurol 2017; 16: 311–322.
37.
Camilo O, Goldstein LB: Seizures and epilepsy after ischemic stroke. Stroke 2004; 35: 1769–1775.
38.
So EL, Annegers JF, Hauser WA, O’Bien PC, Whisnant JP: Population-based study of seizure disorders after cerebral infarction. Neurology 1995; 46: 350–355.
39.
Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C: Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997; 315: 1582–1587.
40.
Cleary P, Shorvon S, Tallis R: Late-onset seizures as a predictor of subsequent stroke. Lancet 2004; 363: 1184–1186.
41.
Annegers JF, Hauser WA, Elveback LR: -Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729–737.
42.
Sillanpää M, Schmidt D: Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006; 129: 617–624.
43.
Bergey GK: Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004; 63(10 suppl 4):S40–S48.
44.
Giussani G, Canelli V, Bianchi E, Erba G, Franchi C, Nobili A, Sander JW, Beghi E; EPIRES Group: Long-term prognosis of epilepsy, prognostic patterns and drug resistance: a population-based study. Eur J Neurol 2016; 23: 1218–1227.
45.
Beghi E, Giussani G, Sander JW: The natural history and prognosis of epilepsy. Epileptic Disord 2015; 17: 243–253.
46.
Hesdorffer DC, Benn EK, Cascino GD, Hauser WA: Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50: 1102–1108.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.